Membranes from stably transfected cell lines that express two point mutations of the human organic cation transporter-1 (hOCT1), R488 M and G465R, have been immobilized on the immobilized artificial membrane (IAM) liquid chromatographic stationary phase to form two cellular membrane affinity chromatography (CMAC) columns, CMAC(hOCT1 G465R ) and CMAC(hOCT1 R488M ). Columns were created using both stationary phases, and frontal displacement chromatography experiments were conducted using [ ) and includes the hOCT1, hOCT2, hOCT3, and hOCTN1 subtypes [4, 5] . These proteins are found in the liver, kidney, and intestine, and they play a major role in the metabolism and excretion of clinically important therapeutics, endogenous compounds, and toxic substances [4] [5] [6] .
variations in a DNA sequence. Recent studies have associated SNP variations in receptor proteins with susceptibility to diseases such as Alzheimer's [1] and schizophrenia [2] , and a relationship between brain function and genomic SNP factors has been demonstrated using functional magnetic resonance imaging and SNP arrays [3] . SNP variants can also affect the activities of enzymes and drug transporters such as the human organic cation transporter (hOCT) SLC22 family [4] [5] [6] [7] . The SLC22 family is composed of transporters that mediate the bidirectional transport of small organic cations (50-350 amu) such as tetraethylammonium (TEA) and 1-methyl-4-phenylpyridinium (MPP + ) and includes the hOCT1, hOCT2, hOCT3, and hOCTN1 subtypes [4, 5] . These proteins are found in the liver, kidney, and intestine, and they play a major role in the metabolism and excretion of clinically important therapeutics, endogenous compounds, and toxic substances [4] [5] [6] .
The effect of SNP variations on the transport activity of the hOCT subtypes has been investigated by following the transport of [
14 C] TEA and [ 3 H] MPP + in oocytes [4, 5] , MDCK cells [5] , or HEK293 cells [7] transfected with the SNP variants. The data indicate that the effect on hOCT transport is dependent on the type and position of the mutation. For example, Kang and coworkers [4] expressed four hOCT1 and three hOCT2 SNP variants in oocytes, and two of the four hOCT1 variants and all of the hOCT2 variants showed decreased [ The results indicated that the effect of an SNP variation on transport activity was a function of the type and location of the amino acid substitution [5] .
It has been demonstrated that hOCT transport can be competitively inhibited by a diverse group of commonly administered drugs, including verapamil, quinidine, quinine, and disopyramide [8] . This inhibition is also stereoselective, as has been demonstrated by functional studies [8, 9] and chromatographic studies [9] [10] [11] . In the latter studies, membrane fragments from a stably transfected MDCK cell line expressing hOCT1 were immobilized on an immobilized artificial membrane stationary phase to create a cellular membrane affinity chromatography (CMAC) column, CMAC(hOCT1) [9] [10] [11] . This technique and the experimental procedures associated with the creation and use of CMAC columns have been reviewed recently [12] .
In the current study, membrane fragments obtained from stably transfected MDCK cell lines expressing two hOCT1 SNP variants, R488 M and G465R [5] , were used to create two CMAC columns, CMAC(hOCT1 R488M ) and CMAC(hOCT1 G465R ). These proteins were chosen because the R488 M substitution did not affect transport function, whereas the G465R mutant exhibited decreased function [5] . The results of this study indicate that CMAC(hOCT1 G465R ) retained the ability to stereoselectively bind a set of chiral ligands and that this observed selectivity was the same as for the wild-type hOCT1, CMAC(hOCT1). CMAC(hOCT1 R488M ) also retained the ability to stereoselectively bind the chiral ligands, but with a selectivity that was opposite to that observed on the CMAC(hOCT1) and CMA-C(hOCT1 G465R ) columns. The data were used to refine the previously reported pharmacophore model of the stereoselective binding to hOCT1 [9] . Immobilized artificial membrane (IAM) stationary phase (12 lm particle size, 300 Å pore size) was purchased from Regis Technologies (Morton Grove, IL, USA). HR 5/2 glass columns were purchased from Amersham Pharmacia Biotech (Uppsala, Sweden).
Materials and methods

Materials
(R)-Verapamil, (S)-verapamil, (R)-isoproterenol, (S)-isoprotere- nol,
Cell lines
MDCK cells stably transfected with complementary DNA (cDNA) expressing the hOCT1-G465R and hOCT1-R488 M SNPs have been described previously [5] and were provided by K. Giacomini (Department of Biopharmaceutical Sciences, University of California, San Francisco).
Preparation of CMAC(hOCT1 R488M ) and CMAC(hOCT1 G465R ) columns
The CMAC(hOCT1 R488M ) and CMAC(hOCT1 G465R ) columns were prepared following the previously reported method for the creation of the CMAC(hOCT1) column [10, 12] . In brief, solubilized membranes were prepared from hOCT1-R488 M and hOCT1-G465R cells (100 Â 10 6 cells). The solution containing the solubilized membranes was added to 160 mg of the IAM stationary phase, and the resulting mixture was rotated at room temperature for 3 h at 150 rpm using an orbit shaker and then dialyzed against Tris-HCl (50 mM, pH 7.4) containing 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), and 1 mM benzamidine for 2 days. The resulting mixture was centrifuged for 3 min at 4°C at 700g, and the supernatant was discarded. The stationary phase pellet was washed with Tris-HCl (10 mM, pH 7.4) containing 1 mM CaCl 2 and 0.5 mM MgCl 2 and was centrifuged. This process was repeated until the supernatant was clear. The stationary phase (160 mg) was packed into an HR 5/2 glass column to yield a 150 Â 5-mm (i.d.) chromatographic bed.
Chromatographic studies
The chromatographic studies were carried out as described previously [10, 12] . In brief, the CMAC(hOCT1 R488M ) and CMA-C(hOCT1 G465R ) columns were connected to an LC-10AD isocratic high-performance liquid chromatography (HPLC) pump (Shimadzu, Columbia, MD, USA). The mobile phase consisted of Tris-HCl (10 mM, pH 7.4) containing 1 mM CaCl 2 and 0.5 mM MgCl 2 delivered at 0.2 ml/min at room temperature. Detection of the marker ligand 
Data analysis
The dissociation constants, K d , for the displacer ligands were calculated using an approach described previously [12] . The data were analyzed by nonlinear regression with a sigmoidal response curve using Prism 4 software (GraphPad Software, San Diego, CA, USA) running on a personal computer.
Molecular modeling
Pharmacophore modeling was carried out using Catalyst software (version 4.11, Accelrys Software, San Diego, CA, USA) as described previously [9] . All of the modeling was carried out on an SGI workstation (Octane) running an IRIX 6.5.28 m operating system and having a 400-MHz processor with a MIPS R12 K CPU. The Catalyst module HypoGen was used to construct the models. The models presented in this study were created by modifying the basic pharmacophore (see Fig. 2 ) consisting of a hydrophobic site, a positive ion site, and two hydrogen bond acceptor sites (HBA1 and HBA2). Two new pharmacophore models were created manually from this basic model: one in which the HBA1 site was removed and the HBA2 site was retained (HBA1(-) model) and one in which the HBA2 site was removed and the HBA1 site was retained (HBA2(-) model). The new pharmacophore models [HBA1(-) and HBA2(-)] were created, and the analyses were carried out using Accelrys Discovery Studio software (version 2.5). Discovery Studio was installed on a Dell Precision PWS380 with an Intel Pentium CPU of 3 GHz and 1 GB of RAM running Windows XP.
Results and discussion
The preparation and use of CMAC columns were reviewed recently, and the experimental protocols were presented and discussed [12] . In brief, in frontal chromatography, a marker ligand that is specific for the immobilized target is placed in the mobile phase and passed through the column, and then elution profiles containing front and plateau regions are obtained. The frontal region is the relatively flat initial portion of the chromatographic trace that reflects the binding of the marker to the target up to saturation, which is represented by a vertical breakthrough and attainment of a plateau region. In a competitive displacement study, increasing concentrations of a competing ligand are added to the mobile phase, the effects on the retention volume of the marker (measured at the midpoint of the breakthrough curves) are determined, and the affinity of the displacer (K d value) for the site(s) that the marker binds can be calculated from the rela-tionship between displacer concentration and changes in the retention volume, as can the number of active binding sites, B max .
In this study, the immobilized targets were hOCT1-R488 M and hOCT1-G465R and the specific marker ligand was [ Because membrane fragments, and not purified proteins, are used to create CMAC columns, both specific and nonspecific interactions can occur between the marker ligand and the immobilized membrane. In the initial studies with the CMAC(hOCT1) column, the membranes used to create the stationary phase were obtained from a stably transfected MDCK cell line [10] . A control column was also prepared using membrane fragments obtained for native MDCK cells, CMAC(MDCK). The data from the initial study indicated that the marker ligand, [ 3 H] MPP + , bound to both nonspecific and specific sites, other than hOCT1, on the CMAC(MDCK) column. The results also indicated that, even in the presence of these background interactions, the affinities of specific hOCT1 ligands for the immobilized transporter could be determined and were directly comparable to data obtained from cellular uptake studies (r 2 = 0.9987, P < 0.001) [10] . Because the membranes used in this study were obtained from MDCK cells stably expressing hOCT1-R488 M or hOCT1-G465R [5] , it was assumed that the same background interactions would be present in the CMAC(hOCT1 R488M ) and CMAC(hOCT1 G465R ) columns. The initial studies with the CMAC(hOCT1) column also demonstrated that the binding of some chiral inhibitors to the immobilized transporter was stereoselective [9] [10] [11] and that this stereoselectivity was reflected in enantioselective functional inhibition of hOCT1 transport [11] . Because the physicochemical properties of enantiomeric compounds are essentially equivalent, and because the background interactions with the MDCK membranes should be consistent between the hOCT1-containing CMAC columns, the enantioselectivities of the CMAC(hOCT1), CMA-C(hOCT1 R488M ), and CMAC(hOCT1 G465R ) columns were used to characterize the effects of the SNP variations on the binding of ligands to the proteins. Thus, the K d values of (R)-and (S)-verapamil, (R)-and (S)-isoproterenol, (R,R)-and (S,S)-fenoterol, and (R,S)-and (S,R)-fenoterol were determined on the CMAC(hOCT1 R488M ) and CMAC(hOCT1 G465R ) columns and compared with previously reported data obtained on the CMAC(hOCT1) column [9] (Table 1) . Although the physicochemical properties of diastereomers are not assumed to be equivalent, the K d values of the diastereomers quinine and quinidine were also determined on the CMA-C(hOCT1 R488M ) column (Table 1) .
Frontal displacement curves of the 
values calculated for (R)-and (S)-verapamil, (R,R)-and (S,S)-fenoterol, and (R,S)-and (S,R)-fenoterol calculated from
the displacement studies on the CMAC(hOCT1 G465R ) column did not significantly differ from the affinities determined using the CMAC(hOCT1) column (Table 1) . The enantioselectivities and diastereoselectivities of the binding interactions were determined as the relative affinities (e.g.,
expressed as the stereoselectivity factor . The observed a values for the compounds used in this study did not significantly differ from the results obtained on the CMAC(hOCT1) column ( Table 2 ). The data indicate that although the transport activity of the hOCT1-G465R mutant was reduced by the alteration, the binding of the inhibitors used in this study was not affected. Table 1 ). However, the binding affinities of (R)-verapamil, (S,S)-fenoterol, and quinidine were decreased, whereas the affinities of (R,S)-fenoterol, (S)-isoproterenol, and (R)-isoproterenol were increased, although the effect on the K d of (S)-isoproterenol was greater than that on (R)-isoproterenol ( Table 1 ). The observed a values for all of the compounds were affected, although the changes in a were less than 2-fold for (R,S)-isoproterenol and (S,R)/(R,R)-fenoterol (Table 2). The results of this study indicate that the binding of compounds to hOCT1-R488 M can be significantly altered relative to wild-type hOCT1. Because hOCT1-R488 M is an active transporter and the compounds used in this study represent some clinically relevant compounds, the results suggest that the CMAC approach can be used to screen the effect of SNP variations on potential drug-drug interactions. CMAC(hOCT1)-determined stereoselectivity has been previously used to construct a pharmacophore model that describes and predicts stereoselective binding to hOCT1 [11] . The resulting Table 1 Binding affinities and K d values of compounds used in this study for the immobilized hOCT1 and hOCT1-G465R and hOCT1-R448 M SNP variants determined on CMAC(hOCT1), CMAC(hOCT1 G465R ), and CMAC(hOCT1 R448M ) columns. model was composed of a positive ion interaction site, a hydrophobic interaction site, and two hydrogen bond acceptor sites (HBA1 and HBA2) (Fig. 2) . In this model, (R)-verapamil mapped to all four of the postulated sites, whereas (S)-verapamil mapped to only three sites (the positive ion, hydrophobic, and HBA2 sites). The observed enantioselectivity was attributed to the mapping of the nitrile moiety on the chiral carbon of (R)-verapamil to the HBA1 site, whereas the corresponding interaction was not achieved by the (S)-enantiomer [9, 11, 13] .
In the hOCT1-G465R variant, the replacement of a neutral glycine residue by a basic arginine moiety had no effect on the enantiomeric selectivity of verapamil on the CMAC(hOCT1 G465R ) 
Table 2
Stereoselective binding to immobilized hOCT1 and hOCT1-G465R and hOCT1-R448 M SNP variants determined using cellular membrane chromatography on CMAC(hOCT1), CMAC(hOCT1 G465R ), and CMAC(hOCT1 R488M ) columns. column. Because the G465 residue is believed to be located on the intracellular portion of the protein [5] , the data suggest that the G465R mutation is located far enough from the inhibitor binding site to have any effect on the binding interactions, and so this residue interaction cannot be part of the previously proposed pharmacophore. Conversely, the substitution of a basic arginine residue for a neutral methionine residue in hOCT1-R488 M had a significant effect on the enantioselective binding of (R)-and (S)-verapamil to the CMAC(hOCT1 R488M ) column because the removal of the potential hydrogen bond accepting site reduced the affinity of (R)-verapamil by nearly 40-fold but had no significant effect on the binding of the (S)-enantiomer (Table 1) . These results suggest that the R488 M mutation may affect the HBA1 or HBA2 site in the proposed pharmacophore. This possibility was explored through the creation of two new pharmacophore models: HBA1(-) and HBA2(-). The enantiomers of verapamil were docked in both of the revised pharmacophores (Figs. 3 and 4, respectively), and both of the enantiomers mapped to the three sites in the respective models (a positive ion interaction site, a hydrophobic interaction site, and a hydrogen bond acceptor site). The calculated activities of the (R)-and (S)-verapamil complexes with the HBA1(-) model were similar at 2.73 and 2.91 lM, respectively, indicating that the model did not reflect enantioselectivity in the binding interactions. When (R)-verapamil was docked into the HBA2(-) model, the estimated activity was 1.81 lM, whereas the calculated activity of the (S)-verapamil complex was 4.50 lM. The results obtained with the HBA2(-) model pharmacophore are consistent with chromatographic data and suggest that the site identified as HBA2 in the proposed hOCT1 pharmacophore is associated with R488 in the hOCT1 protein. The data are also consistent with the previously postulated conformation-driven chiral recognition mechanism Fig. 2 . Pharmacophore model (reprinted from Ref. [9] ) in which the red sphere represents a positive ion interaction site, the blue sphere represents a hydrophobic interaction site, and the green spheres represent two hydrogen bond acceptor sites (HBA1 and HBA2). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) describing enantioselective ligand-hOCT1 interactions observed on the CMAC(hOCT1) column [13] . In this mechanism, chiral recognition is a multistep process involving an initial tethering of the ligand to the hOCT1 protein, probably at the positive ion interaction site, followed by conformational adjustments that produce the optimum interactions with a combination of the hydrophobic, HBA1, and HBA2 sites. The observed enantioselectivities are the result of the relative conformational energies required to optimize the binding interactions.
